← Back to Press PAGE

Cure51's CEO Nicolas Wolikow: How does AI help advance our Rosalind Study?

Cure51

Publication Date:

Mar 3, 2026

How does AI help advance our Rosalind Study? Our CEO Nicolas Wolikow breaks it down in an interview with FW.MEDIA.

Credit: FW.MEDIA

Nicolas Wolikow, CEO

Updated: March 3, 2026

Table of Contents

NEWS

THEY SPREAD THE WORD

Go to Press page

Simon Istolainen and Nicolas Wolikow: The History of Cure51 and the Vision Behind a New Model in Oncology

Simon Istolainen and Nicolas Wolikow: The History of Cure51 and the Vision Behind a New Model in Oncology

Celebrating a huge Rosalind Study milestone: 115+ worldwide partner oncology centers!

Rosalind Study Milestone: 115+ Centers Join Cure51’s International Oncology Network

Nicolas-Wolikow-AI-Rosalind-Study

Nicolas-Wolikow-AI-Rosalind-Study

Cure51's CEO Nicolas Wolikow: How does AI help advance our Rosalind Study?

Mar 3, 2026

READ MORE

Join us to eradicate Cancer.

Join us to eradicate Cancer.

Join us to eradicate Cancer.

Join us to eradicate Cancer.

Contact us